Change in GLOESS from baseline to week 12 showed a numerical trend toward a treatment difference favoring secukinumab vs. placebo in all three clusters.
← all excerpts
Exploring clusters based on ultrasound-detected inflammation in patients with psoriatic arthritis: a post-hoc analysis from the ULTIMATE trial.
1
—
—